In IgA Nephropathy and FSGS

Proteinuria Could Be Putting Your Patients at High Risk

Proteinuria is a key prognostic indicator of progression in both IgA nephropathy and FSGS1-8

Proteinuria perpetuates a cycle of kidney fibrosis, as proximal tubular reabsorption of excess protein contributes to tubulointerstitial injury5,7,8

Reduction in proteinuria results in a decrease in glomerular pressure and reduction of podocyte damage.1

Lower proteinuria levels are critical to preserving kidney function1,9,10

TARGETED PROTEINURIA GOALS1,3

IgA nephropathy
Downward pointing arrows to signify the importance of lowering proteinuria to targeted levels
<1.0 g/d
FSGS
Downward pointing arrows to signify the importance of lowering proteinuria to targeted levels
<1.5 g/ga
Achieving these targeted proteinuria goals correlates with extended kidney survival

aFSGS partial remission threshold defined as <1.5 g/g with a 40% reduction from baseline.

Evidence-based thresholds translate to clinically meaningful treatment goals

Despite receiving standard-of-care treatment, many patients face a poor prognosis due to elevated proteinuria levels, making the need for novel medications urgent.1

Explore the role of ET-1 and Ang II

Ang II=angiotensin II; ET-1=endothelin-1; FSGS=focal segmental glomerulosclerosis; IgA=immunoglobulin A.

References:

1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kidney Int. 2021;100(4S):S1-S276. 2. Troyanov S, et al. J Am Soc Nephrol. 2005;16:1061-1068. 3. Inker LA, et al. Am J Kidney Dis. 2016:1-10. 4. D’Agati VD, et al. New Engl J Med. 2011;365:2398-2411. 5. Remuzzi G, et al. New Engl J Med. 1998;339:1448-1456. 6. Ruggenenti P, et al. Kidney Int. 1998;53:1209-1216. 7. Dhaun N, et al. Br J Pharmacol. 2012;167:720-731. 8. Cravedi P, et al. Br J Clin Pharmacol. 2013;76(4):516-523. 9. Troost JP, et al. Am J Kidney Dis. 2021;77:216-225. 10. Troost JP, et al. Clin J Am Soc Nephrol. 2018;13:414-421. 11. Komers R, et al. Am J Physiol Regul Integr Comp Physiol. 2016:R877-R884. 12. Kohan DE, et al. Kidney Int. 2014;86:896-904. 13. Raina R, et al. Kidney Dis. 2020;6:22-34.

Sign up for the latest news and updates on IgA nephropathy and FSGS

All fields are required.

Specialty

    I understand that by checking this box and clicking "Submit," I am submitting my contact information and may receive company communications from Travere Therapeutics™.

    All personal data will be processed by or on behalf of Travere to provide access to company information and to respond to requests. Travere will retain personal data only for as long as is required to complete the purposes for which it was collected and to fulfill its legal, regulatory, or reporting obligations. Travere understands personal data is private and will not disseminate it to third parties who are not providing services to Travere. You may unsubscribe at any time. For more information, review the Travere privacy policies.

        Sign up successful

        Thank you for registering

        Back to the top